Jump to content

Damalie Nakanjako

From Wikipedia, the free encyclopedia

Damalie Nakanjako
Born1974 (age 49–50)
Uganda
NationalityUgandan
EducationMakerere University
(Bachelor of Medicine and Bachelor of Surgery)
(Master of Medicine in Internal Medicine)
University of Antwerp
(Doctor of Philosophy
Occupations
Years active2000–present
Known forAcademics and Research
TitlePrincipal and Professor of Medicine at Makerere University College of Health Sciences

Damalie Nakanjako, (born 1974) is a Ugandan specialist physician, internist, immunologist, infectious diseases consultant, academic and researcher, who serves as the Principal and Professor of Medicine at Makerere University College of Health Sciences.[1] Immediately prior to her present position, she served as Dean of Makerere University School of Medicine, from 2019 until 17 February 2021.[2]

Background and education

[edit]

She was born in the Buganda Region of Uganda in the 1970s. After attending Maryhill High School and later Gayaza High School, she was admitted to Makerere University, where she studied human medicine. She graduated with a Bachelor of Medicine and Bachelor of Surgery (MBChB) degree in 1999. She followed that with a Master of Medicine (MMed) degree in Internal Medicine, also from Makerere University. Her third degree was a Doctor of Philosophy (PhD) in Biomedical Science, obtained from the University of Antwerp, in Belgium, in 2010. According to her online curriculum vitae, she spent the years between 2011 and 2013 at the Infectious Diseases Institute, working as a postdoctoral fellow and at Uganda Virus Research Institute, working as a research scholar.[3]

Career

[edit]

Nakanjako interned at Mulago Hospital in Internal Medicine and Obstetrics and Genecology, from 1998 until 1999. She spent another year at the same hospital as a medical officer. She then spent two years as a specialist medical officer at the CDC field station in Tororo, Uganda. In 2002, she returned to Mulago to pursue her master's degree.[3]

After her MMed studies she focused on clinical research in HIV/AIDS and she started lecturing in internal medicine at Makerere in 2007. Following her PhD studies, the Welcome Trust awarded her a scholarship to undertake a postdoctoral fellowship at Makerere, based at the Infectious Diseases Institute of the university.[3]

Makerere University appointed Nakanjako as Associate Professor of Medicine in 2013, serving in that capacity for five years. In 2018, she made full Professor.[3] She is the scientific Director of the Translational laboratory at the Infectious Diseases Institute, Makerere University College of Health Sciences. Professor Nakanjako is the Director of the ADAPT Africa One Health Network with Seven countries in sub-Saharan Africa and Germany https://adaptonehealth.net/our-team/#uganda and she leads the Africa-Europe Cluster of Excellence in Infection Immunity and Inflammation Research https://www.the-guild.eu/africa-europe-core/Translational%20Research-in-Infection-Immunity-an-Inflammation.html. Professor Damalie Nakanjako is a receipient of the 2022 TWAS-Abdool Karim Award in Biological Sciences, in recognition of her achievements in biological sciences. The award recognizes women scientists from low-income African countries

Other considerations

[edit]

Professor Nakanjako has authored or co-written over 100 peer-reviewed articles, in the areas of her medical expertise in different medical journals.[4] Some of them include; Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells.[5] Access to HIV/AIDS care for mothers and children in sub-Saharan Africa: adherence to the postnatal PMTCT program.[6] Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention.[7] Subclinical Atherosclerosis among HIV-Infected Adults Attending HIV/AIDS Care at Two Large Ambulatory HIV Clinics in Uganda.[8] Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda.[9] Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a National Referral Hospital in Kampala, Uganda.[10] High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort.[11] Use of RDTs to improve malaria diagnosis and fever case management at primary health care facilities in Uganda.[12] Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.[13] Mentorship needs at academic institutions in resource-limited settings: a survey at makerere university college of health sciences.[14] Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.[15] Challenges faced by caregivers of virally non-suppressed children on the intensive adherence counselling program in Uganda: a qualitative study.[16] Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda.[17] Acceptability and predictors of uptake of Anti-retroviral Pre-exposure Prophylaxis (PrEP) among fishing communities in Uganda: A cross-sectional discrete choice experiment survey.[18] Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to evaluate AIDS in East Africa.[19] and Strategies for retention of heterosexual men in HIV care in sub-Saharan Africa: A systematic review.[20]

See also

[edit]

References

[edit]
  1. ^ MUCHS (21 April 2021). "Collège Profile of Makerere University Collège of Health Sciences (MUCHS)". Kampala. Retrieved 21 April 2021.
  2. ^ Brenda Namatta (8 February 2021). "Dr. Nakimuli Takes Over Leadership of School of Medicine". Kampala: Makerere University School of Medicine. Archived from the original on 23 July 2021. Retrieved 21 April 2021.
  3. ^ a b c d Damalie Nakanjako (2019). "Curriculum Vitae of Professor Damalie Nakanjako, Makerere College of Health Sciences". University of California. Archived from the original (Cached from the original on 21 April 2021) on 23 April 2021. Retrieved 21 April 2021.
  4. ^ Researchgate (21 April 2021). "Partial Listing of Publications By Professor Damalie Nakanjako". Retrieved 21 April 2021.
  5. ^ Nabatanzi, Rose; Cose, Stephen; Joloba, Moses; Jones, Sarah Rowland; Nakanjako, Damalie (15 March 2018). "Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells". AIDS Research and Therapy. 15 (1): 7. doi:10.1186/s12981-018-0194-y. ISSN 1742-6405. PMC 5853105. PMID 29544508.
  6. ^ Nassali, Mercy; Nakanjako, Damalie; Kyabayinze, Daniel; Beyeza, Jolly; Okoth, Anthony; Mutyaba, Twaha (1 September 2009). "Access to HIV/AIDS care for mothers and children in sub-Saharan Africa: adherence to the postnatal PMTCT program". AIDS Care. 21 (9): 1124–1131. doi:10.1080/09540120802707467. ISSN 0954-0121. PMID 20024771.
  7. ^ Bayigga, Lois; Kateete, David P.; Anderson, Deborah J.; Sekikubo, Musa; Nakanjako, Damalie (1 February 2019). "Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention". American Journal of Obstetrics and Gynecology. 220 (2): 155–166. doi:10.1016/j.ajog.2018.10.014. ISSN 0002-9378. PMC 10715630.
  8. ^ Ssinabulya, Isaac; Kayima, James; Longenecker, Chris; Luwedde, Mary; Semitala, Fred; Kambugu, Andrew; Ameda, Faith; Bugeza, Sam; McComsey, Grace; Freers, Juergen; Nakanjako, Damalie (28 February 2014). "Subclinical Atherosclerosis among HIV-Infected Adults Attending HIV/AIDS Care at Two Large Ambulatory HIV Clinics in Uganda". PLOS ONE. 9 (2): e89537. doi:10.1371/journal.pone.0089537. ISSN 1932-6203. PMC 3938501. PMID 24586854.
  9. ^ Nasuuna, Esther; Kigozi, Joanita; Babirye, Lillian; Muganzi, Alex; Sewankambo, Nelson K.; Nakanjako, Damalie (22 August 2018). "Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda". BMC Public Health. 18 (1): 1048. doi:10.1186/s12889-018-5964-x. ISSN 1471-2458. PMC 6103875. PMID 30134880.
  10. ^ Nakanjako, Damalie; Kamya, Moses; Daniel, Kyabayinze; Mayanja-Kizza, Harriet; Freers, Jurgen; Whalen, Christopher; Katabira, Elly (1 September 2007). "Acceptance of Routine Testing for HIV among Adult Patients at the Medical Emergency Unit at a National Referral Hospital in Kampala, Uganda". AIDS and Behavior. 11 (5): 753–758. doi:10.1007/s10461-006-9180-9. ISSN 1573-3254.
  11. ^ Nakanjako, Damalie; Ssewanyana, Isaac; Mayanja-Kizza, Harriet; Kiragga, Agnes; Colebunders, Robert; Manabe, Yukari C.; Nabatanzi, Rose; Kamya, Moses R.; Cao, Huyen (8 February 2011). "High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort". BMC Infectious Diseases. 11 (1): 43. doi:10.1186/1471-2334-11-43. ISSN 1471-2334. PMC 3065409. PMID 21299909.
  12. ^ Kyabayinze, Daniel J.; Asiimwe, Caroline; Nakanjako, Damalie; Nabakooza, Jane; Counihan, Helen; Tibenderana, James K. (12 July 2010). "Use of RDTs to improve malaria diagnosis and fever case management at primary health care facilities in Uganda". Malaria Journal. 9 (1): 200. doi:10.1186/1475-2875-9-200. ISSN 1475-2875. PMC 2914063. PMID 20624312.
  13. ^ Mermin, Jonathan; Lule, John; Ekwaru, John Paul; Malamba, Samuel; Downing, Robert; Ransom, Ray; Kaharuza, Frank; Culver, David; Kizito, Francis; Bunnell, Rebecca; Kigozi, Aminah; Nakanjako, Damalie; Wafula, Winnie; Quick, Robert (16 October 2004). "Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda". The Lancet. 364 (9443): 1428–1434. doi:10.1016/S0140-6736(04)17225-5. ISSN 0140-6736.
  14. ^ Nakanjako, Damalie; Byakika-Kibwika, Pauline; Kintu, Kenneth; Aizire, Jim; Nakwagala, Fred; Luzige, Simon; Namisi, Charles; Mayanja-Kizza, Harriet; Kamya, Moses R. (29 July 2011). "Mentorship needs at academic institutions in resource-limited settings: a survey at makerere university college of health sciences". BMC Medical Education. 11 (1): 53. doi:10.1186/1472-6920-11-53. ISSN 1472-6920. PMC 3170866. PMID 21801406.
  15. ^ Nakanjako, Damalie; Ssinabulya, Isaac; Nabatanzi, Rose; Bayigga, Lois; Kiragga, Agnes; Joloba, Moses; Kaleebu, Pontiano; Kambugu, Andrew D.; Kamya, Moses R.; Sekaly, Rafick; Elliott, Alison; Mayanja-Kizza, Harriet (2015). "Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial". Tropical Medicine & International Health. 20 (3): 380–390. doi:10.1111/tmi.12442. PMC 4529480. PMID 25441397.
  16. ^ Nasuuna, Esther; Kigozi, Joanita; Muwanguzi, Patience A.; Babirye, Joyce; Kiwala, Laura; Muganzi, Alex; Sewankambo, Nelson; Nakanjako, Damalie (7 March 2019). "Challenges faced by caregivers of virally non-suppressed children on the intensive adherence counselling program in Uganda: a qualitative study". BMC Health Services Research. 19 (1): 150. doi:10.1186/s12913-019-3963-y. ISSN 1472-6963. PMC 6407183. PMID 30845951.
  17. ^ Nakiyingi, Lydia; Ssengooba, Willy; Nakanjako, Damalie; Armstrong, Derek; Holshouser, Molly; Kirenga, Bruce J.; Shah, Maunank; Mayanja-Kizza, Harriet; Joloba, Moses L.; Ellner, Jerrold J.; Dorman, Susan E.; Manabe, Yukari C. (15 February 2015). "Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda". BMC Infectious Diseases. 15 (1): 62. doi:10.1186/s12879-015-0812-4. ISSN 1471-2334. PMC 4332438. PMID 25888317.
  18. ^ Kuteesa, Monica O.; Quaife, Mathew; Biraro, Sam; Katumba, Kenneth R.; Seeley, Janet; Kamali, Anatoli; Nakanjako, Damalie (1 October 2019). "Acceptability and Predictors of Uptake of Anti-retroviral Pre-exposure Prophylaxis (PrEP) Among Fishing Communities in Uganda: A Cross-Sectional Discrete Choice Experiment Survey". AIDS and Behavior. 23 (10): 2674–2686. doi:10.1007/s10461-019-02418-7. ISSN 1573-3254.
  19. ^ Nakanjako, Damalie; Kiragga, Agnes N.; Musick, Beverly S.; Yiannoutsos, Constantin T.; Wools-Kaloustian, Kara; Diero, Lameck; Oyaro, Patrick; Lugina, Emanuel; Ssali, John C.; Kambugu, Andrew; Easterbrook, Philippa (31 July 2016). "Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa". AIDS. 30 (12): 1913–1922. doi:10.1097/QAD.0000000000001085. ISSN 0269-9370. PMC 5438045. PMID 26959510.
  20. ^ Kusemererwa, Sylvia; Akena, Dickens; Nakanjako, Damalie; Kigozi, Joanita; Nanyunja, Regina; Nanfuka, Mastula; Kizito, Bennet; Okello, Joseph Mugisha; Sewankambo, Nelson Kawulukusi (4 February 2021). "Strategies for retention of heterosexual men in HIV care in sub-Saharan Africa: A systematic review". PLOS ONE. 16 (2): e0246471. doi:10.1371/journal.pone.0246471. ISSN 1932-6203. PMC 7861356. PMID 33539424.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Damalie_Nakanjako&oldid=1257533559"